Light source module for stereoscopic display, imaging device for stereoscopic display and stereoscopic display system
    1.
    发明授权
    Light source module for stereoscopic display, imaging device for stereoscopic display and stereoscopic display system 有权
    用于立体显示的光源模块,用于立体显示的成像装置和立体显示系统

    公开(公告)号:US09158122B2

    公开(公告)日:2015-10-13

    申请号:US13817471

    申请日:2010-09-08

    IPC分类号: G02B27/26 H04N13/04 G02B27/10

    摘要: A light source module for stereoscopic display includes multi-primary color lasers which output the light with the same polarization direction. Respective lasers are divided into two groups according to the wavelengths of the output light. A light combiner is provided in the output light path of each laser group and is used for combining the output light of all lasers in the group into one output light path. The light source module further includes a polarization conversion rotary member, and the polarization direction of the two output light is periodically and alternately rotated by 90 degree by self-rotation of the polarization conversion rotary member. An imaging device for stereoscopic display includes the light source module for stereoscopic display, the light combiner and a first optical imaging modulator and a second optical imaging modulator. A stereoscopic display system includes the imaging device for stereoscopic display and a projection lens sub-system.

    摘要翻译: 用于立体显示的光源模块包括以相同偏振方向输出光的多原色激光器。 相应的激光器根据输出光的波长分为两组。 在每个激光组的输出光路中设置一个组合器,用于将该组中所有激光器的输出光组合成一个输出光路。 光源模块还包括偏振转换旋转构件,并且通过偏振转换旋转构件的自旋,两个输出光的偏振方向周期性地并且交替旋转90度。 用于立体显示的成像装置包括用于立体显示的光源模块,光组合器和第一光学成像调制器和第二光学成像调制器。 立体显示系统包括用于立体显示的成像装置和投影透镜子系统。

    New Optically Pure Compounds for Improved Therapeutic Efficiency
    2.
    发明申请
    New Optically Pure Compounds for Improved Therapeutic Efficiency 有权
    用于提高治疗效果的新型光学纯化合物

    公开(公告)号:US20110201559A1

    公开(公告)日:2011-08-18

    申请号:US12993427

    申请日:2008-05-22

    摘要: The present invention relates to new optically pure compounds displaying an improved anticancer activity compared to previously known complex mixtures of stereoisomers thereof. Such compounds are of formula (I): wherein each X independently represents any amino acid; n is 0 or 1; m is an integer between 0 and 3; k is an integer of at least 3; Psi is a reduced bond of formula replacing the peptide amide bond between Lys and Pro; and wherein Lys residues in pseudopeptide units of said compound of formula (I) are either all in L configuration or all in D configuration. A method for preparing such compounds, and therapeutic uses thereof are also provided. The synthetic method involves the selective reduction of the peptide bond between Lys and Pro in a dipeptide intermediate with borane. The therapeutic uses are against cancer, inflammation and for wound healing.

    摘要翻译: 本发明涉及与先前已知的其立体异构体的复合混合物相比显示改善的抗癌活性的新的光学纯化合物。 这样的化合物具有式(I):其中每个X独立地表示任何氨基酸; n为0或1; m是0和3之间的整数; k是至少3的整数; Psi是取代Lys和Pro之间的肽酰胺键的式的还原键; 并且其中所述式(I)化合物的假肽单元中的Lys残基全部为L构型或全部为D构型。 还提供了制备这些化合物的方法及其治疗用途。 合成方法包括用二硼化物中间体与硼烷选择性还原Lys和Pro之间的肽键。 治疗用途是针对癌症,炎症和伤口愈合。

    Method for the manufacture of degarelix
    3.
    发明授权
    Method for the manufacture of degarelix 有权
    地加瑞克的制造方法

    公开(公告)号:US08828938B2

    公开(公告)日:2014-09-09

    申请号:US13265402

    申请日:2010-04-26

    IPC分类号: C07K7/23

    CPC分类号: C07K7/23

    摘要: In a step-wise synthesis of degarelix comprising 0.3% by weight or less of 4-([2-(5-hydantoyl)]acetylamino)-phenylalanine analog on (solid support)-NH2 a step comprises providing a solution of an amino acid or peptide of which the α-amino group is protected by Fmoc; contacting the support with the solution in the presence of reagent for forming a peptide bond between a carboxyl group of the amino acid or peptide and (solid support)-NH2; removing Fmoc by contacting the support with an organic base, in particular piperidine, in an organic solvent. Also disclosed is degarelix of high purity prepared by the method of the invention and the use of Fmoc in the synthesis of degarelix.

    摘要翻译: 在(在固体支持物)-NH 2上包含0.3重量%或更少的4 - ([2-(5-乙酰基)]乙酰氨基) - 苯丙氨酸类似物的地加瑞克的逐步合成步骤包括提供氨基酸 或其α-氨基被Fmoc保护的肽; 在用于形成氨基酸或肽的羧基与(固体支持物)-NH 2之间的肽键的试剂存在下使载体与溶液接触; 通过使载体与有机碱,特别是哌啶在有机溶剂中接触来除去Fmoc。 还公开了通过本发明的方法制备的高纯度的地加瑞克,以及在地加瑞克合成中使用Fmoc。

    METHOD FOR THE MANUFACTURE OF DEGARELIX
    4.
    发明申请
    METHOD FOR THE MANUFACTURE OF DEGARELIX 有权
    制造方法

    公开(公告)号:US20120041172A1

    公开(公告)日:2012-02-16

    申请号:US13265402

    申请日:2010-04-26

    CPC分类号: C07K7/23

    摘要: In a step-wise synthesis of degarelix comprising 0.3% by weight or less of 4-([2(5-hydantoyl)]acetylamino)-phenylalanine analog on (solid support)-NH2 a step comprises providing a solution of an amino acid or peptide of which the α-amino group is protected by Fmoc; contacting the support with the solution in the presence of reagent for forming a peptide bond between a carboxyl group of the amino acid or peptide and (solid support)-NH2; removing Fmoc by contacting the support with an organic base, in particular piperidine, in an organic solvent. Also disclosed is degarelix of high purity prepared by the method of the invention and the use of Fmoc in the synthesis of degarelix.

    摘要翻译: 在逐步合成包含0.3重量%或更少的(固体支持物)-NH 2上的4 - ([2(5-乙酰基)]乙酰氨基) - 苯丙氨酸类似物的地加瑞克,步骤包括提供氨基酸或 α-氨基被Fmoc保护的肽; 在用于在氨基酸或肽的羧基与(固体支持物)-NH 2之间形成肽键的试剂存在下使载体与溶液接触; 通过使载体与有机碱,特别是哌啶在有机溶剂中接触来除去Fmoc。 还公开了通过本发明的方法制备的高纯度的地加瑞克,以及在地加瑞克合成中使用Fmoc。